GSK's third-quarter results delivered a top- and bottom-line beat, yet the market reaction was negative as investors zeroed in on pipeline credibility and disappointing vaccine sales.
By mid-afternoon trading the company's London-listed shares were down about 4% by 14:30 GMT after an earlier intraday fall of 7.3%, placing the stock on course for its steepest single-day decline since April. The share price movement largely reversed gains accumulated since Luke Miels became chief executive in January.
Management has been pursuing a sizeable strategic overhaul under Mr. Miels, which included a £1.9 billion cost-savings programme announced in July intended to free cash for drug development and to prepare the group for impending patent expiries - an issue affecting many peers across the sector. Despite those measures, investors remain unconvinced about the sources of future growth.
Market consensus for 2031 sales stands at £36.64 billion, notably below GSK's stated ambition of exceeding £40 billion in annual revenue by that year. That gap has heightened investor scrutiny of how the company will meet its targets.
Verso Investment Management analyst James Eugene commented on the recent results, saying that while progress on cost control is broadly positive, "it suggests the outperformance is almost entirely driven by cost timings rather than underlying business momentum." He added, "Pipeline credibility is more of a medium-term concern."
After the results, CEO Luke Miels told journalists the company is "playing a very long-term game" and will remain focused on operational delivery, execution and accelerating R&D. "We just need to keep executing, putting one foot in front of the other and quietly getting on with it," he said.
Drivers of the quarter
GSK said that sales of specialty medicines - covering HIV, respiratory conditions and cancer - rose 15% and provided the main contribution to the quarterly turnover beat for the three months ended September 30. However, revenues from recently launched asthma medicine Exdensur and from the company's vaccines division underperformed relative to expectations. The vaccines shortfall included weaker sales of the shingles vaccine Shingrix.
The group maintained its full-year guidance but flagged that R&D spending is expected to grow at a faster rate than sales. As part of its development plans GSK expects to initiate 22 late-stage studies by the end of 2026, 18 of which are currently underway, with a focus on specialty medicines and vaccines.
GSK is actively working to reduce dependence on its flagship HIV therapy dolutegravir, which faces patent expiries between 2028 and 2030. Management is developing longer-acting options such as Apretude, which market participants are monitoring closely.
On medium-term guidance, GSK expects 2026 turnover growth to fall in the upper half of its established 3% to 5% range, while core earnings per share are projected to grow in the lower half of its 7% to 9% range.
Restructuring and charges
As part of the strategic reset, GSK has signalled it will redeploy resources toward new medicines, including through workforce reductions as it rebuilds its oncology franchise, which management sees as a significant longer-term contributor. The company said its announced actions would have a "limited" impact in the United Kingdom after disclosing plans this month to cut 1,217 jobs in Belgium.
Details of the restructuring were limited, though Mr. Miels said the company was "slightly ahead" of plan on the programme. GSK recorded a charge of £328 million related to the restructuring in the quarter.
Financial results
GSK reported core profit of 54.6 pence per share on turnover of £8.89 billion, both above analysts' expectations of 50.4 pence and £8.84 billion respectively. The company included a currency conversion reference of $1 = 0.7527 pounds in its reporting.
While the headline numbers beat consensus, investor concern has skewed toward whether the business can sustain organic momentum beyond cost-driven gains and how the pipeline will replace revenue lost to patent expiration.